Manuel Hidalgo Medina
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Manuel Hidalgo Medina | |
|---|---|
| Known for |
|
| Scientific career | |
| Fields | oncology |
| Institutions | Beth Israel Deaconess Medical Center |
Manuel Hidalgo Medina is an oncologist. He is director of the Leon V. and Marilyn L. Rosenberg Clinical Cancer Center at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in the United States; he also heads its hematology/oncology division.[1] He specializes in pancreatic cancer. His research has included development of anti-cancer drugs such as erlotinib, nab-paclitaxel and temsirolimus, and the development of patient-derived tumor xenograft models.[1]
Recognition
[edit]Hidalgo received a research grant from the American Society of Clinical Oncology Conquer Cancer Foundation in 2001.[2]
References
[edit]- ^ a b Manuel Hidalgo Medina, MD, PhD. Boston. Archived 1 August 2019.
- ^ "Grant and Award Recipients".